Patents by Inventor Tannin A. Schmidt

Tannin A. Schmidt has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11752194
    Abstract: Disclosed are compositions and methods involving the use of PRG4 protein, also known as lubricin, to mechanically inhibit biological processes involving cell motility and adhesion. The methods and compositions may be used to develop a variety of specific therapies and compositions, often exploited through surgical procedures, where development of the pathology involves one or more of the following modes of action: 1) the passage of cells from one body compartment to another, 2) adherence of macrophages to substrates such as fibrin or exposed extra cellular matrix, 3) binding of platelets to fibrin, or 4) failure of function of the glycocalyx on exposed epithelial cell surfaces, e.g., within the vasculature.
    Type: Grant
    Filed: March 9, 2021
    Date of Patent: September 12, 2023
    Assignee: Lubris LLC
    Inventors: Gregory D. Jay, Tannin A. Schmidt, Benjamin D. Sullivan
  • Publication number: 20230234999
    Abstract: Disclosed are new recombinant isoforms of human-like lubricin or PRG4 glycoprotein having outstanding lubrication properties and a novel glycosylation pattern, and methods for their manufacture at high levels enabling commercial production.
    Type: Application
    Filed: October 27, 2022
    Publication date: July 27, 2023
    Inventors: Tannin A. Schmidt, Gregory D. Jay
  • Patent number: 11485764
    Abstract: Disclosed are new recombinant isoforms of human-like lubricin or PRG4 glycoprotein having outstanding lubrication properties and a novel glycosylation pattern, and methods for their manufacture at high levels enabling commercial production.
    Type: Grant
    Filed: June 18, 2020
    Date of Patent: November 1, 2022
    Assignee: Lubris LLC
    Inventors: Tannin A. Schmidt, Gregory D. Jay
  • Publication number: 20220023380
    Abstract: Disclosed are compositions and methods involving the use of PRG4 protein, also known as lubricin, to mechanically inhibit biological processes involving cell motility and adhesion. The methods and compositions may be used to develop a variety of specific therapies and compositions, often exploited through surgical procedures, where development of the pathology involves one or more of the following modes of action: 1) the passage of cells from one body compartment to another, 2) adherence of macrophages to substrates such as fibrin or exposed extra cellular matrix, 3) binding of platelets to fibrin, or 4) failure of function of the glycocalyx on exposed epithelial cell surfaces, e.g., within the vasculature.
    Type: Application
    Filed: March 9, 2021
    Publication date: January 27, 2022
    Inventors: Gregory D. Jay, Tannin A. Schmidt, Benjamin D. Sullivan
  • Publication number: 20210169990
    Abstract: The present invention provides a pharmaceutical composition, and methods of use thereof, for treating ocular boundary deficiency, symptoms associated therewith, or an undesired condition that is associated with or causes ocular boundary deficiency at the ocular surface. The pharmaceutical composition of the present invention comprises a human PRG4 protein, a lubricant fragment, homolog, or isoform thereof, suspended in an ophthalmically acceptable balanced salt solution. The pharmaceutical composition of the present invention may also comprise one or more ophthalmically acceptable agents selected from the group consisting of an ophthalmically acceptable demulcent, excipient, astringent, vasoconstrictor, emollient, sodium hyaluronate, hyaluronic acid, and surface active phospholipids, in a pharmaceutically acceptable carrier for topical administration.
    Type: Application
    Filed: May 23, 2019
    Publication date: June 10, 2021
    Inventors: Benjamin Sullivan, Tannin A. Schmidt, David A. Sullivan
  • Publication number: 20210130427
    Abstract: Disclosed are new recombinant isoforms of human-like lubricin or PRG4 glycoprotein having outstanding lubrication properties and a novel glycosylation pattern, and methods for their manufacture at high levels enabling commercial production.
    Type: Application
    Filed: June 18, 2020
    Publication date: May 6, 2021
    Inventors: Tannin A. Schmidt, Gregory D. Jay
  • Patent number: 10960047
    Abstract: Disclosed are compositions and methods involving the use of PRG4 protein, also known as lubricin, to mechanically inhibit biological processes involving cell motility and adhesion. The methods and compositions may be used to develop a variety of specific therapies and compositions, often exploited through surgical procedures, where development of the pathology involves one or more of the following modes of action: 1) the passage of cells from one body compartment to another, 2) adherence of macrophages to substrates such as fibrin or exposed extra cellular matrix, 3) binding of platelets to fibrin, or 4) failure of function of the glycocalyx on exposed epithelial cell surfaces, e.g., within the vasculature.
    Type: Grant
    Filed: November 21, 2019
    Date of Patent: March 30, 2021
    Assignee: Lubris LLC
    Inventors: Gregory D. Jay, Tannin A. Schmidt, Benjamin D. Sullivan
  • Publication number: 20200368328
    Abstract: The present invention provides a pharmaceutical composition, and methods of use thereof, for treating ocular boundary deficiency, symptoms associated therewith, or an undesired condition that is associated with or causes ocular boundary deficiency at the ocular surface. The pharmaceutical composition of the present invention comprises a human PRG4 protein, a lubricant fragment, homolog, or isoform thereof, suspended in an ophthalmically acceptable balanced salt solution. The pharmaceutical composition of the present invention may also comprise one or more ophthalmically acceptable agents selected from the group consisting of an ophthalmically acceptable demulcent, excipient, astringent, vasoconstrictor, emollient, sodium hyaluronate, hyaluronic acid, and surface active phospholipids, in a pharmaceutically acceptable carrier for topical administration.
    Type: Application
    Filed: May 23, 2019
    Publication date: November 26, 2020
    Inventors: Benjamin Sullivan, Tannin A. Schmidt, David A. Sullivan
  • Patent number: 10723773
    Abstract: Disclosed are new recombinant isoforms of human-like lubricin or PRG4 glycoprotein having outstanding lubrication properties and a novel glycosylation pattern, and methods for their manufacture at high levels enabling commercial production.
    Type: Grant
    Filed: November 7, 2018
    Date of Patent: July 28, 2020
    Assignee: Lubris LLC
    Inventors: Tannin A. Schmidt, Gregory D. Jay
  • Publication number: 20200215156
    Abstract: Disclosed are compositions and methods involving the use of PRG4 protein, also known as lubricin, to mechanically inhibit biological processes involving cell motility and adhesion. The methods and compositions may be used to develop a variety of specific therapies and compositions, often exploited through surgical procedures, where development of the pathology involves one or more of the following modes of action: 1) the passage of cells from one body compartment to another, 2) adherence of macrophages to substrates such as fibrin or exposed extra cellular matrix, 3) binding of platelets to fibrin, or 4) failure of function of the glycocalyx on exposed epithelial cell surfaces, e.g., within the vasculature.
    Type: Application
    Filed: November 21, 2019
    Publication date: July 9, 2020
    Inventors: Gregory D. Jay, Tannin A. Schmidt, Benjamin D. Sullivan
  • Publication number: 20190270783
    Abstract: Disclosed are new recombinant isoforms of human-like lubricin or PRG4 glycoprotein having outstanding lubrication properties and a novel glycosylation pattern, and methods for their manufacture at high levels enabling commercial production.
    Type: Application
    Filed: November 7, 2018
    Publication date: September 5, 2019
    Inventors: Tannin A. Schmidt, Gregory D. Jay
  • Patent number: 10125180
    Abstract: Disclosed are new recombinant isoforms of human-like lubricin or PRG4 glycoprotein having outstanding lubrication properties and a novel glycosylation pattern, and methods for their manufacture at high levels enabling commercial production.
    Type: Grant
    Filed: October 22, 2014
    Date of Patent: November 13, 2018
    Assignee: Lubris LLC
    Inventors: Tannin A. Schmidt, Gregory D. Jay
  • Publication number: 20180028598
    Abstract: The present invention provides a pharmaceutical composition, and methods of use thereof, for treating ocular boundary deficiency, symptoms associated therewith, or an undesired condition that is associated with or causes ocular boundary deficiency at the ocular surface. The pharmaceutical composition of the present invention comprises a human PRG4 protein, a lubricant fragment, homolog, or isoform thereof, suspended in an ophthalmically acceptable balanced salt solution. The pharmaceutical composition of the present invention may also comprise one or more ophthalmically acceptable agents selected from the group consisting of an ophthalmically acceptable demulcent, excipient, astringent, vasoconstrictor, emollient, sodium hyaluronate, hyaluronic acid, and surface active phospholipids, in a pharmaceutically acceptable carrier for topical administration.
    Type: Application
    Filed: July 10, 2017
    Publication date: February 1, 2018
    Inventors: Benjamin Sullivan, Tannin A. Schmidt, David A. Sullivan
  • Patent number: 9730978
    Abstract: The present invention provides a pharmaceutical composition, and methods of use thereof, for treating ocular boundary deficiency, symptoms associated therewith, or an undesired condition that is associated with or causes ocular boundary deficiency at the ocular surface. The pharmaceutical composition of the present invention comprises a human PRG4 protein, a lubricant fragment, homolog, or isoform thereof, suspended in an ophthalmically acceptable balanced salt solution. The pharmaceutical composition of the present invention may also comprise one or more ophthalmically acceptable agents selected from the group consisting of an ophthalmically acceptable demulcent, excipient, astringent, vasoconstrictor, emollient, sodium hyaluronate, hyaluronic acid, and surface active phospholipids, in a pharmaceutically acceptable carrier for topical administration.
    Type: Grant
    Filed: April 6, 2016
    Date of Patent: August 15, 2017
    Assignees: Thc Regents of the University of California, Schepens Eye Research Institute
    Inventors: Benjamin Sullivan, Tannin A. Schmidt, David A. Sullivan
  • Patent number: 9585936
    Abstract: The present invention provides a pharmaceutical composition, and methods of use thereof, for treating ocular boundary deficiency, symptoms associated therewith, or an undesired condition that is associated with or causes discomfort at the ocular surface. The pharmaceutical composition of the present invention comprises a human PRG4 protein, or a lubricating fragment thereof, suspended in an ophthalmically acceptable vehicle. The pharmaceutical composition of the present invention may also comprise one or more ophthalmically acceptable agents selected from the group consisting of an ophthalmically acceptable demulcent, excipient, astringent, vasoconstrictor, emollient, sodium hyaluronate, hyaluronic acid, and surface active phospholipids, in a pharmaceutically acceptable carrier for topical administration.
    Type: Grant
    Filed: December 18, 2015
    Date of Patent: March 7, 2017
    Assignees: The Regents of the University of California, Schepens Eye Research Institute
    Inventors: Benjamin Sullivan, Tannin A. Schmidt, David A. Sullivan
  • Publication number: 20160304572
    Abstract: Disclosed are new recombinant isoforms of human-like lubricin or PRG4 glycoprotein having outstanding lubrication properties and a novel glycosylation pattern, and methods for their manufacture at high levels enabling commercial production.
    Type: Application
    Filed: October 22, 2014
    Publication date: October 20, 2016
    Inventors: Tannin A. Schmidt, Gregory D. Jay
  • Patent number: 9421241
    Abstract: Provided herein are ophthalmically acceptable pharmaceutical compositions comprising PRG4 or lubricant fragments and a PRG4 inducing compound. The PRG4 inducing compound in the pharmaceutical composition of the present invention upregulates PRG4 expression and localization in the ocular surface for efficient surface boundary lubrication. In some instances, pharmaceutical compositions described herein are utilized for treating ophthalmic conditions, e.g., ocular boundary deficiency and symptoms associated therewith.
    Type: Grant
    Filed: August 20, 2015
    Date of Patent: August 23, 2016
    Assignees: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, SCHEPENS EYE RESEARCH INSTITUTE
    Inventors: Benjamin Sullivan, Tannin A. Schmidt, David A. Sullivan
  • Publication number: 20160235809
    Abstract: The present invention provides a pharmaceutical composition, and methods of use thereof, for treating ocular boundary deficiency, symptoms associated therewith, or an undesired condition that is associated with or causes ocular boundary deficiency at the ocular surface. The pharmaceutical composition of the present invention comprises a human PRG4 protein, a lubricant fragment, homolog, or isoform thereof, suspended in an ophthalmically acceptable balanced salt solution. The pharmaceutical composition of the present invention may also comprise one or more ophthalmically acceptable agents selected from the group consisting of an ophthalmically acceptable demulcent, excipient, astringent, vasoconstrictor, emollient, sodium hyaluronate, hyaluronic acid, and surface active phospholipids, in a pharmaceutically acceptable carrier for topical administration.
    Type: Application
    Filed: April 6, 2016
    Publication date: August 18, 2016
    Inventors: Benjamin Sullivan, Tannin A. Schmidt, David A. Sullivan
  • Patent number: 9393285
    Abstract: The present invention provides a pharmaceutical composition, and methods of use thereof, for treating ocular boundary deficiency, symptoms associated therewith, or undesired condition that is associated with or causes ocular boundary deficiency at the ocular surface. The pharmaceutical composition of the present invention comprises a human PRG4 protein, a lubricant fragment, homolog, or isoform thereof, suspended in an ophthalmically acceptable balanced salt solution. The pharmaceutical composition of the present invention may also comprise one or more ophthalmically acceptable agents selected from the group consisting of an ophthalmically acceptable demulcent, excipient, astringent, vasoconstrictor, emollient, sodium hyaluronate, hyaluronic acid, and surface active phospholipids, in a pharmaceutically acceptable carrier for topical administration.
    Type: Grant
    Filed: November 5, 2010
    Date of Patent: July 19, 2016
    Assignees: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, SCHEPENS EYE RESEARCH INSTITUTE
    Inventors: Benjamin Sullivan, Tannin A. Schmidt, David A. Sullivan
  • Publication number: 20160101149
    Abstract: The present invention provides a pharmaceutical composition, and methods of use thereof, for treating ocular boundary deficiency, symptoms associated therewith, or an undesired condition that is associated with or causes discomfort at the ocular surface. The pharmaceutical composition of the present invention comprises a human PRG4 protein, or a lubricating fragment thereof, suspended in an ophthalmically acceptable vehicle. The pharmaceutical composition of the present invention may also comprise one or more ophthalmically acceptable agents selected from the group consisting of an ophthalmically acceptable demulcent, excipient, astringent, vasoconstrictor, emollient, sodium hyaluronate, hyaluronic acid, and surface active phospholipids, in a pharmaceutically acceptable carrier for topical administration.
    Type: Application
    Filed: December 18, 2015
    Publication date: April 14, 2016
    Inventors: Benjamin Sullivan, Tannin A. Schmidt, David A. Sullivan